|
Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC). |
|
|
No Relationships to Disclose |
|
|
Honoraria - Boehringer Ingelheim |
|
|
Consulting or Advisory Role - Ultragenyx Pharmaceuticals |
|
|
Honoraria - Genentech; Roche Pharma AG |
Consulting or Advisory Role - Genentech; Roche Pharma AG |
Research Funding - Genentech; Roche Pharma AG |
Travel, Accommodations, Expenses - Genentech; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca |
Expert Testimony - AstraZeneca |
|
|
Honoraria - Roche Pharma AG |
Consulting or Advisory Role - AstraZeneca; Novartis; Roche/Genentech |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Roche/Genentech (Inst) |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Sanofi |
|
|
Honoraria - Roche Pharma AG |
Consulting or Advisory Role - AstraZeneca; Roche Pharma AG |
Speakers' Bureau - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
Honoraria - Roche Pharma AG |
Consulting or Advisory Role - Amgen; Novartis; Oxigene |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Sanofi |
|
|
Stock and Other Ownership Interests - GlaxoSmithKline |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Johnson & Johnson; Procter & Gamble |
Consulting or Advisory Role - Endocyte |
Patents, Royalties, Other Intellectual Property - Elsevier; UpToDate |